4D Molecular Therapeutics reported its financial results for the first quarter of 2025 on May 8, 2025, along with operational highlights and expected upcoming milestones. The company announced a net loss of $48.0 million for the quarter, an increase from a net loss of $32.4 million in the first quarter of 2024. This rise in losses was primarily driven by increased research and development expenses.
Research and development expenses for the first quarter of 2025 were $40.7 million, up from $27.9 million in the prior-year period. This increase was mainly due to the initiation of the first Phase 3 clinical trial of 4D-150 in wet AMD, including higher personnel and professional services to support Phase 3 development. General and administrative expenses also increased to $12.9 million from $10.3 million in the same period of 2024.
As of March 31, 2025, cash, cash equivalents, and marketable securities totaled $458 million. Despite the net decrease from the previous quarter due to cash used in operations, the company reiterated its expectation that this capital is sufficient to fund planned operations into 2028. This extended runway is crucial for delivering topline results from both wet AMD Phase 3 clinical trials in the second half of 2027 without requiring additional capital.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.